The Board of Alibaba Health Information Technology Limited announced that with effect from the conclusion of the AGM held on August 11, 2023, Mr. Luo Tong (Mr. Luo) has retired from his position as an independent non-executive Director at the AGM. Accordingly, Mr. Luo has ceased to act as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee; Mr. Wong King On, Samuel (Mr. Wong) has retired from his position as an independent non-executive Director at the AGM. Accordingly, Mr. Wong has ceased to act as an independent
non-executive Director, the chairman of the Audit Committee and a member of each of the Nomination Committee and the Remuneration Committee; Dr. Shao Rong (Dr. Shao') has been appointed as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee by the Shareholders at the AGM to fill the vacancy arising from the retirement of Mr. Luo; and Ms. Wu May Yihong (Ms. Wu') has been appointed as an independent non-executive Director, the chairman of the Audit Committee and a member of each of the Nomination
Committee and the Remuneration Committee by the Shareholders at the AGM to fill the vacancy arising from the retirement of Mr. Wong. The Board announced that Ms. Chun Ka Yan (Ms. Chun) has tendered her resignation as the company secretary of the Company and will cease to
act as an authorized representative of the Company. Ms. Chun has tendered her resignation in order to focus on other business affairs of
Alibaba Group Holdings Limited and its subsidiaries. The Board announced that, following the resignation of Ms. Chun, Ms. Deng
Yan (Ms. Deng) and Ms. Tsui Hiu Leong (Ms. Tsui) have been appointed as the joint company secretaries of the Company with effect from August 12, 2023. Ms. Tsui has also been appointed as the Authorized Representative and Process Agent with effect from August 12, 2023. Ms. Deng has been a qualified lawyer in the PRC since March 2013. She has more than 20 years of working experience and has extensive experience in the legal field. She first joined the Group as senior legal counsel in December 2016 and has been the general counsel of the Group since June 2019 and is responsible for leading the legal and compliance department of the Group and overseeing all legal and compliance matters of the Company. Prior to joining the Group, Ms. Deng was the legal counsel at the legal and compliance department of Alibaba Group from June 2014 to December 2016 and was responsible for handling legal matters related to the food, drug and medical devices sold on Tmall and Taobao platforms. Prior to joining Alibaba Group, from March 2003 to June 2014, she worked in multiple positions at Beijing Haihong Pharmacy E-Commerce Company Limited, a wholly owned subsidiary of
Searainbow Holding Corp. (currently known as China Reform Health Management and Services Group Co. Ltd. which is a company listed on the Shenzhen Stock Exchange with her last position as deputy general manager. She obtained a Bachelor's degree in Law in June 2003 from the Minzu University of China in the PRC and a Master's degree in Civil and Commercial Law in January 2011 from Peking University in the PRC. Ms. Tsui joined the Company in January 2023 as a legal counsel. Ms. Tsui has extensive experience in advising listed companies on mergers and acquisitions, corporate finance and compliance of the Listing Rules and securities and corporate laws. Prior to joining the Company, she worked for Guantao & Chow Solicitors and Notaries as a practising solicitor from 2018 to 2022. Ms. Tsui obtained a Bachelor's degree in Law from Jinan University in the PRC, a Master's degree in Common Law from The University of Hong Kong and a Bachelor's degree in Law from Manchester Metropolitan University in the
United Kingdom. She was admitted as a solicitor of the High Court of Hong Kong in 2018 and is currently a member of the Law Society of Hong Kong. Dr. Shao Rong, aged 60, has extensive experience in the pharmaceutical industry. She currently holds various positions in China Pharmaceutical University of the People's Republic of China, serving as the executive deputy director of its Research Center of National Drug Policy and Ecosystem and the executive dean of its Institute of Drug Regulatory Sciences, in charge of regulatory science disciplines and research. Dr. Shao has been an independent non-executive director of YSB Inc., a company listed on the Main Board of the Stock Exchange since June 2023. Dr. Shao has also been an independent director of Jiangsu GDK Biotechnology Co. Ltd. and I-Mab since June 2020 and June 2021, respectively. She was also an independent director of Changzhou Qianhong Biopharma Co. Ltd. from September 2014 to January 2021. Dr. Shao obtained a Bachelor's degree in
Medicinal Chemistry in July 1983 from Nanjing College of Pharmacy in the PRC, a second Bachelor's degree in Law in July 1989 from Nanjing University in the PRC and a PhD degree in Pharmacy in July 2010 from Shenyang Pharmaceutical University in the PRC. Dr. Shao is a qualified lawyer in the PRC, licensed by the Jiangsu Justice Department in 2009 and is a holder of a Professor Qualification Certificate awarded by the Jiangsu Provincial Department of Education in August 2003. She is currently a director of the China Society for Drug Regulation, chairman of the Special Committee on Drug Regulatory Laws and Policies and a vice chairman of the Special Committee on Drug Regulatory Talent Training. Ms. Wu May Yihong formerly named as Wu Ning, aged 55, has been an independent director and chairwoman of the compensation committee of Noah Holdings Limited and the Main Board of the Stock Exchange since November 2010 and May 2015, respectively. Since May 2017, Ms. Wu has been an independent non-executive director and chairman of the audit committee of Swire Properties Limited. Ms. Wu worked at Homeinns Hotel Group from October 2006 to April 2016, where she served as their board adviser from July 2019 to May 2023, chief strategy officer from May 2010 to June 2019 and chief financial officer from July 2006 to April 2010. Ms. Wu obtained a Bachelor's degree in Biochemistry in July 1989 from Fudan University in the PRC, a Master's degree of Arts in Economics in June 1993 from the Brooklyn College of the City University of New York, and a Master's degree in Business Administration in June 1998 from the J.L. Kellogg Graduate School of Management of Northwestern University in the United States of America.